Fuzhou Hanli Biomedical Technology

Fuzhou Hanli Biomedical Technology is a clinical-stage biotechnology company focused on developing innovative cell therapies for solid tumors. The company specializes in chimeric antigen receptor T-cell (CAR-T) technology, with a primary focus on addressing unmet needs in gastrointestinal and liver cancers. Its lead candidate, HL-001, is a GPC3-targeted CAR-T therapy currently undergoing clinical evaluation for advanced hepatocellular carcinoma. Hanli Biomedical utilizes proprietary antibody screening and cell modification platforms to enhance the efficacy and safety of its immunotherapies. Based in Fuzhou, China, the company integrates research, development, and manufacturing to advance its pipeline of oncology treatments.